Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. Fu Y, et al. Among authors: rathod d. Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504. Pharmaceutics. 2019. PMID: 31581483 Free PMC article.
Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.
Fu Y, Rathod D, Patel K. Fu Y, et al. Among authors: rathod d. Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6. Exp Cell Res. 2020. PMID: 32898554
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
Rathod D, Fu Y, Patel K. Rathod D, et al. Eur J Pharm Sci. 2019 Oct 1;138:105039. doi: 10.1016/j.ejps.2019.105039. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394259
Feedback